Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Avastin Best-Selling Drug in Japan in August: Encise Snapshot
September 12, 2018
- Risankizumab Hits Primary Endpoint in Japan PII/III Study with Psoriasis Vulgaris Patients: AbbVie
September 11, 2018
- Power Back On at Drug Makers’ Hokkaido Plants
September 11, 2018
- Tremfya Meets Primary Endpoint in Japan PIII Study for Palmoplantar Pustulosis: Janssen
September 11, 2018
- Ethical Drug Sales Up 3.6% in July: Crecon
September 11, 2018
- Shionogi Loses HIV Patent Battle against MSD
September 10, 2018
- Hokkaido Quake Hits Wholesaler Price Negotiations as Sept. Deadline for Medical Fee Cuts Looms
September 10, 2018
- Sanofi to Focus on Increasing Prescriptions of Lantus XR Based on Results of Head-to-Head Comparison Study
September 10, 2018
- Xofluza Cuts Flu Symptoms, Vial Loads: Shionogi
September 7, 2018
- Ono to Divide Oncology Sales Force into Two Units as Opdivo Label Expands
September 7, 2018
- Giant Quake Disrupts Drug Production, Shipments in Hokkaido; Distributors Scramble to Ensure Supplies
September 7, 2018
- Huahai Already Developed New Manufacturing Process for Valsartan API, Says Japan Chief after JMA Criticism on Impurity Issue
September 6, 2018
- Sawai’s Abilify Generic Approved for Bipolar Disorder
September 6, 2018
- Lenvima Gets China OK for 1st Line HCC: Eisai/Merck
September 6, 2018
- I/O in Lung Cancer - 4: Bristol-Myers Looks to Regain Ground for Opdivo with Immunotherapy Combos
September 5, 2018
- FDA Snubs Sunovion’s ADHD Drug
September 4, 2018
- Life Science Institute to Initiate Exploratory Clinical Study of Muse Cell Product for Cerebral Infarction
September 4, 2018
- Thrombocytopenia Drug Mulpleta Now Available in US: Shionogi
September 3, 2018
- Yamaha Motor to Invest in Biotech Evec to Strengthen Presence in Biomedical Field
September 3, 2018
- Taisho’s Voluntary Early Retirement Program Attracts 948 Applicants
September 3, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…